Jan Hillson

Title: Jan Hillson: Innovator in Immunological Therapeutics

Introduction

Jan Hillson is a notable inventor based in Cambridge, MA, who has made significant contributions to the field of immunology. His work primarily focuses on the development of antibodies that target the human neonatal Fc receptor (FcRn). With one patent to his name, Hillson's innovations are paving the way for new therapeutic approaches to treat various immunological diseases.

Latest Patents

Hillson's patent, titled "FcRn antibodies and methods of use thereof," features antibodies that bind to the human neonatal Fc receptor. These anti-FcRn antibodies have multiple applications, including promoting the clearance of autoantibodies, suppressing antigen presentation, and blocking immune responses. Additionally, they are useful in treating immunological diseases, such as autoimmune disorders. The patent also highlights the potential of these antibodies to decrease pathogenic antibody transport across the placenta and enhance antibody catabolism in pregnant subjects, thereby addressing antibody-mediated enhancement of viral diseases in fetuses and neonates.

Career Highlights

Jan Hillson is currently associated with Momenta Pharmaceuticals, Inc., where he continues to advance his research in immunological therapeutics. His innovative work has positioned him as a key figure in the development of new treatments that could significantly improve patient outcomes in autoimmune diseases.

Collaborations

Hillson collaborates with talented professionals in his field, including Leona E Ling and Sucharita Roy. Their combined expertise contributes to the ongoing research and development efforts at Momenta Pharmaceuticals.

Conclusion

Jan Hillson's contributions to immunology through his patent on FcRn antibodies exemplify the impact of innovative research in the medical field. His work not only addresses critical health challenges but also opens new avenues for therapeutic interventions.